Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
about
Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patientsGefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutationLow EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutationEnhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinomaMass spectrometry-based proteomics: the road to lung cancer biomarker discovery.Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy.EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancer.Lung cancer proteomics: recent advances in biomarker discoveryProgression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibEpidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis.The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activationAfatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatmentTobacco Smoking and Lung Cancer: Perception-changing factsA potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting.Bearings in Hip Arthroplasty: Joint Registries vs Precision Medicine: Review Article.A new frontier in personalized cancer therapy: mapping molecular changes.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Phosphorylation events during viral infections provide potential therapeutic targets.Bioinformatics Meets Biomedicine: OncoFinder, a Quantitative Approach for Interrogating Molecular Pathways Using Gene Expression Data.Cancer subtypes classification using long non-coding RNAPTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.Rest/activity rhythm is related to the coexistence of pain and sleep disturbance among advanced cancer patients with pain.Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats.Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling.
P2860
Q21245661-2FEC12E2-5280-43E0-BD2A-CD337D387F9CQ26739096-F808E908-0A53-4F9D-9459-F116D9D5CF4FQ27853221-5D67DEB6-41CB-4B3B-827C-82C39C2FFA6DQ28545198-79C48266-E193-467F-8933-BA9D46F24B6AQ33693476-A92F6A6E-3458-45B5-A142-139A3146BBA6Q34031219-6962299F-F517-479A-A0CD-3F4527ABACA8Q34350615-256F7777-FC23-4C66-B4AB-F572FB6379CCQ34498746-08288C74-18D9-4C9D-A187-4AA9703519CFQ34747045-C46D7DA7-D362-47D6-A2E4-4869CDE25715Q34777840-0F6FD873-DF91-4A3C-89DC-2DF14060AA6FQ35200329-47828787-0EA8-4EBF-881D-38B63DE7C310Q35389059-757D7DD1-FBE2-4DD8-A1FE-951DB2BB8E71Q35632548-605D78C9-9587-4C1D-B428-40EBB97FE181Q35807946-13A66601-E3A5-4413-B8B1-EAB6BFA4B44BQ36063291-AE7C86D1-15E2-4C0E-A603-48DC696EC7D9Q36200253-8934ADFC-868B-4F7D-90B5-1448EE93B104Q36557305-9A4CB819-AE0C-4605-A365-62B0FB02C2D4Q36673751-99A44E25-C43F-44FB-9CAD-46BB1E4FAB40Q36705603-C7FDB4C9-86E4-4134-A3CC-4D59D20744D0Q36716210-A72C1206-C6E3-4EDE-A3AD-416A4E3CBB09Q37109569-222E47FB-6F1B-4222-BE8E-652CC1D8AE5AQ37528312-8ECD1204-0501-4420-BF39-F2D3C57DE30CQ37605100-2970D061-0CE2-44D2-9BDE-CB446716D619Q37898108-191BBB1B-B737-4A98-942D-C04373BA9662Q37939200-5BACC239-C8EB-4AF4-84E9-DE4F783C7F8DQ37960427-9CD338DB-8B2C-4967-9A2B-AD76FA32C2F5Q38604283-03F2C47F-8D59-4BFE-990A-02CB025F917BQ38848878-207DEE5D-2955-4C0D-A6BB-CFE7103E7534Q38888799-FA06BFD3-0614-4379-A168-623D5E84482BQ46108334-C02A41E7-D244-4652-896F-60BE49CF0DF8Q47754114-60EC9B36-2370-4FE6-815D-0FD24137E9D9Q48157938-C8F83E5F-8F5E-42E7-BCD8-67328831BEBBQ48337835-064285B4-2E27-44C0-8747-B57249570CD3Q53730282-BCB8BBFB-5BCA-4311-9634-303C82479FA0
P2860
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Gefitinib as first-line treatm ...... ation: Review of the evidence.
@en
Gefitinib as first-line treatm ...... ation: Review of the evidence.
@nl
type
label
Gefitinib as first-line treatm ...... ation: Review of the evidence.
@en
Gefitinib as first-line treatm ...... ation: Review of the evidence.
@nl
prefLabel
Gefitinib as first-line treatm ...... ation: Review of the evidence.
@en
Gefitinib as first-line treatm ...... ation: Review of the evidence.
@nl
P2093
P1433
P1476
Gefitinib as first-line treatm ...... ation: Review of the evidence.
@en
P2093
P304
P356
10.1016/J.LUNGCAN.2010.12.008
P577
2011-01-08T00:00:00Z